May 2024
1. TENG Z, Xu S, Lei Q
   [Retracted] Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB?152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
   Oncol Rep. 2024;51:66.
   

   >> Share

   
   December 2023
2. LI J, Tang B, Miao Y, Li G, et al
   Targeting of STAT5 using the small molecule topotecan hydrochloride suppresses acute myeloid leukemia progression.
   Oncol Rep. 2023;50:208.
   

   >> Share

   
   August 2023
3. WANG X, Rong S, Sun Y, Yin B, et al
   NDRG3 regulates imatinib resistance by promoting beta‑catenin accumulation in the nucleus in chronic myelogenous leukemia.
   Oncol Rep. 2023;50:152.
   

   >> Share

   
   May 2023
4. LIU YH, Zhu M, Lei PP, Pan XY, et al
   [Corrigendum] ND‑09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR‑ABL signaling.
   Oncol Rep. 2023;49:81.
   

   >> Share

   
   February 2023
5. LIANG X, Xia R
   [Corrigendum] Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia.
   Oncol Rep. 2023;49:26.
   

   >> Share

   
   December 2022
6. LEONCINI PP, Vitullo P, Reddel S, Tocco V, et al
   MicroRNA profiling of paediatric AML with FLT-ITD or MLL-rearrangements: Expression signatures and in vitro modulation of miR-221-3p and miR-222-3p with BRD4/HATs inhibitors.
   Oncol Rep. 2022;48.
   

   >> Share

   
   August 2022
7. KAEHLER M, Litterst M, Kolarova J, Bohm R, et al
   Genomewide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitorresistant CML cells.
   Oncol Rep. 2022;48.
   

   >> Share

   
   June 2022
8. LALIC H, Aurer I, Batinic D, Visnjic D, et al
   Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).
   Oncol Rep. 2022;47.
   

   >> Share

   
   May 2022
9. FORGIONE MO, McClure BJ, Page EC, Yeung DT, et al
   TP53 lossoffunction mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137.
   Oncol Rep. 2022;47.
   

   >> Share

   
   April 2022
10. LI Z, Zhang J, Zhou M, Li JL, et al
    Epigenetic therapy with chidamide alone or combined with 5azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro.
    Oncol Rep. 2022;47.
    

    >> Share

    
    February 2022
11. HUANG FL, Yu SJ, Liao EC, Li LY, et al
    Niclosamide suppresses Tcell acute lymphoblastic leukemia growth through activation of apoptosis and autophagy.
    Oncol Rep. 2022;47.
    

    >> Share

    
    January 2022
12. LIANG X, Xia R
    Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia.
    Oncol Rep. 2022;47.
    

    >> Share

    
    October 2021
13. AYE KT, Wattanapongpitak S, Supawat B, Kothan S, et al
    Gallic acid enhances pirarubicininduced anticancer in living K562 and K562/Dox leukemia cancer cells through cellular energetic state impairment and Pglycoprotein inhibition.
    Oncol Rep. 2021;46.
    

    >> Share

    
    July 2021
14. YAO J, Luo Y, Zeng C, He H, et al
    UHRF1 regulates the transcriptional repressor HBP1 through MIF in T acute lymphoblastic leukemia.
    Oncol Rep. 2021;46.
    

    >> Share

    
    
15. SHI YF, Huang ZY, Huang YS, Dong RJ, et al
    Interaction between CD9 and PI3Kp85 activates the PI3K/AKT signaling pathway in Blineage acute lymphoblastic leukemia.
    Oncol Rep. 2021;46.
    

    >> Share

    
    
16. LIU YH, Zhu M, Lei PP, Pan XY, et al
    ND09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCRABL signaling.
    Oncol Rep. 2021;46.
    

    >> Share

    
    
17. FU JF, Shih LY, Yen TH
    HOXA11 plays critical roles in disease progression and response to cytarabine in AML.
    Oncol Rep. 2021;46.
    

    >> Share

    
    June 2021
18. DONG L, Xu WW, Li H, Bi KH, et al
    [Retracted] In vitro and in vivo anticancer effects of marmesin in U937 human leukemia cells are mediated via mitochondrialmediated apoptosis, cell cycle arrest, and inhibition of cancer cell migration.
    Oncol Rep. 2021;45.
    

    >> Share

    
    
19. GENG Y, Wu W, Zhou L, Li J, et al
    Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells.
    Oncol Rep. 2021;45.
    

    >> Share

    
    March 2021
20. JING W, Zhou M, Chen R, Ye X, et al
    In vitro and ex vivo anti‑tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2‑overexpressing leukemia cells.
    Oncol Rep. 2021;45:1142-1152.
    

    >> Share

    
    February 2021
21. ZHANG P, Wang Y, Qin M, Li D, et al
    Involvement of Blnk and Foxo1 in tumor suppression in BCRABL1transformed proB cells.
    Oncol Rep. 2021;45:693-705.
    

    >> Share

    
    January 2021
22. GONG Y, Deng J, Wu X
    Germline mutations and blood malignancy (Review).
    Oncol Rep. 2021;45:49-57.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share